You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium oxide
Accession NumberDB01377
TypeSmall Molecule
GroupsApproved
DescriptionMagnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]
Structure
Thumb
Synonyms
Magmitt
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium Citrate Oral Solutionliquid1.75 goralD.C. Labs Limited1951-12-312003-07-11Canada
Magnesium Oxidetablet400 mg/1oralQualitest Pharmaceuticals2003-12-03Not applicableUs
Magnesium Oxidetablet400 mg/1oralPhysicians Total Care, Inc.2004-07-15Not applicableUs
Magnesium Oxidetablet253 mg/1oralQualitest Pharmaceuticals2003-10-06Not applicableUs
Magnesium Oxidetablet400 mg/1oralVirtus Pharmaceuticals2015-09-08Not applicableUs
Magnesium Oxidetablet400 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Magnesium Oxidetablet400 mg/1oralVirtus Pharmaceuticals LLC2014-04-09Not applicableUs
Magnesium Oxidetablet400 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Magnesium Oxide 420 - Caplettablet250 mgoralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Magnesium Oxide Tab 420mgtablet420 mgoralGahler Enterprises Ltd.1988-12-312008-07-17Canada
Magnesium Tab 250mgtablet410 mgoralPharmavite Llc1987-12-312006-07-05Canada
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Active FeGm Pharmaceuticals, Inc.
Aspirin Plus Stomach Guard Ext.stgth.capletSterling Winthrop Inc.
Aspirin Plus Stomach Guard Extra StrengthBayer Inc Consumer Care
Aspirin Plus Stomach Guard TabSterling Winthrop Inc.
Aspirin With Stomach GuardBayer Inc Consumer Care
Aspirin With Stomach Guard Extra Strength - TabBayer Inc Consumer Care
B6 Plus TabVita Health Products Inc
BacminMarnel Pharmaceuticals, Inc.
C-apnto-B6 Vitamins W Magnesium TabMetagenics, Inc.
Calcium - Magnesium - Zinc TabNutristar Health Products (1987) Inc.
Calcium Magnesium Avec Vitamine D Et ZincLes Aliments Nutri Source Inc.
Calcium Magnesium TabNutrilite, A Division Of Access Business Group, Llc
Calcium Vitamin D Iron MagLaboratoire Lalco Inc.
CitracleenLaboratorios Casen Fleet, S.L.U.
Cyclo/magLiving Well Pharmacy, Inc.
Cyclo/mag 10mg/200mgLiving Well Pharmacy, Inc.
Healthy Mamabe Well Rounded Be Well RoundedMATERNAL SCIENCE, LLC
Inatal AdvanceNnodum Pharmaceuticals
Iron Polysaccharides Folic Acid DHAVirtus Pharmaceuticals LLC
Kidmag Vitamins W Magnesium TabMetagenics, Inc.
Magnesium CapAlsi Cie Ltee
Magnesium Comprime TabHerbes Universelles Inc.
Migralex Dr. MauskopMigralex Inc.
Oral PurgativeOdan Laboratories Ltd
Pico-salaxFerring Inc
PicodanOdan Laboratories Ltd
PicofloPharmascience Inc
Pnv-firstAcella Pharmaceuticals, LLC
Pnv-selectAcella Pharmaceuticals, LLC
Prenate EliteAvion Pharmaceuticals, Llc
Prenate EnhanceAvion Pharmaceuticals, Llc
Prenate EssentialAvion Pharmaceuticals, Llc
Prenate RestoreAvion Pharmaceuticals, Llc
Prenate StarAvion Pharmaceuticals, Llc
PrepopikFerring Pharmaceuticals Inc.
Purg-odanOdan Laboratories Ltd
Se-care ChewableSeton Pharmaceuticals
Se-natal OneSeton Pharmaceuticals
Strovite One CapletsEverett Laboratories, Inc.
TriadvanceTrigen Laboratories, Inc.
Trinatal GtTrigen Laboratories, Inc.
Ultimatecare One NfTrigen Laboratories, Inc.
Usana Active CalciumUsana Health Sciences, Inc.
Virt-bal DHA PlusVirtus Pharmaceuticals
Virt-PNVirtus Pharmaceuticals
Virt-PN DHAVirtus Pharmaceuticals
Virt-PN PlusVirtus Pharmaceuticals LLC
Vitafol UltraEverett Laboratories, Inc.
SaltsNot Available
Categories
UNII3A3U0GI71G
CAS number1309-48-4
WeightAverage: 40.304
Monoisotopic: 39.97995652
Chemical FormulaMgO
InChI KeyInChIKey=CPLXHLVBOLITMK-UHFFFAOYSA-N
InChI
InChI=1S/Mg.O
IUPAC Name
oxomagnesium
SMILES
O=[Mg]
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as miscellaneous mixed metal/non-metals. These are inorganic compounds containing non-metal as well as metal atoms but not belonging to afore mentioned classes.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassMiscellaneous mixed metal/non-metals
Sub ClassNot Available
Direct ParentMiscellaneous mixed metal/non-metals
Alternative Parents
Substituents
  • Inorganic oxide
  • Miscellaneous mixed metal/non-metal
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationMagnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.
PharmacodynamicsNot Available
Mechanism of actionThe term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9837
Caco-2 permeable+0.6708
P-glycoprotein substrateNon-substrate0.8922
P-glycoprotein inhibitor INon-inhibitor0.9725
P-glycoprotein inhibitor IINon-inhibitor0.995
Renal organic cation transporterNon-inhibitor0.9248
CYP450 2C9 substrateNon-substrate0.8638
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateNon-substrate0.8026
CYP450 1A2 substrateNon-inhibitor0.8153
CYP450 2C9 inhibitorNon-inhibitor0.9268
CYP450 2D6 inhibitorNon-inhibitor0.9535
CYP450 2C19 inhibitorNon-inhibitor0.9338
CYP450 3A4 inhibitorNon-inhibitor0.9869
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9062
Ames testNon AMES toxic0.7478
CarcinogenicityCarcinogens 0.7198
BiodegradationReady biodegradable0.7705
Rat acute toxicity2.2618 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9031
hERG inhibition (predictor II)Non-inhibitor0.977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit
Capsuleoral
Liquidoral1.75 g
Tabletoral253 mg/1
Tabletoral400 mg/1
Tabletoral250 mg
Tabletoral420 mg
Tabletoral410 mg
Tablet, coatedoral
Powder for solutionoral
Tablet, film coatedoral
Powder, meteredoral
Tabletoral
Tablet, chewableoral
Capsule, gelatin coatedoral
Capsule, liquid filledoral
Prices
Unit descriptionCostUnit
Phillips 500 mg caplet0.18USD caplet
Magnesium oxide 400 mg tablet0.13USD tablet
Magnesium oxide 420 mg tablet0.11USD tablet
Magox 400 tablet0.11USD tablet
Mag-oxide 400 mg tablet0.09USD tablet
Magnesium oxide powder heavy0.05USD g
Magnesium oxide 500 mg tablet0.04USD tablet
Maox 420 mg tablet0.04USD tablet
Magnesium oxide 250 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8450338 No2008-10-102028-10-10Us
US8481083 No2008-10-102028-10-10Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP-1.1ChemAxon
pKa (Strongest Basic)13.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area17.07 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity1.44 m3·mol-1ChemAxon
Polarizability2.88 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Jajnya D. Panda, Santosh K. Mahapatra, “Process for the production of magnesium oxide from brine or bittern.” U.S. Patent US4370422, issued June, 1921.

US4370422
General References
  1. Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R: Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens. 2000 Jul;18(7):919-26. [PubMed:10930190 ]
  2. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999 Jul 15;84(2):152-6. [PubMed:10426331 ]
External Links
ATC CodesA12CC10A06AD02A02AA02
AHFS Codes
  • 88:29.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineMagnesium oxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
3,4-MethylenedioxymethamphetamineMagnesium oxide may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
4-AndrostenedioneThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium oxide.
AcepromazineMagnesium oxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium oxide.
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium oxide.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.
AlfacalcidolThe serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol.
AlimemazineMagnesium oxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolMagnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium oxide.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.
AmphetamineMagnesium oxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide.
AtazanavirMagnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium oxide.
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium oxide.
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium oxide.
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium oxide.
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium oxide.
BenzphetamineMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium oxide.
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide.
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium oxide.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium oxide.
CalcitriolThe serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide.
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide.
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium oxide.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.
ChlorphentermineMagnesium oxide may decrease the excretion rate of Chlorphentermine which could result in a lower serum level and potentially a reduction in efficacy.
ChlorpromazineMagnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium oxide.
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium oxide.
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium oxide.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium oxide.
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium oxide.
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium oxide.
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide.
Coenzyme Q10The serum concentration of Coenzyme Q10 can be decreased when it is combined with Magnesium oxide.
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium oxide.
DasatinibMagnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide.
DehydroepiandrosteroneThe bioavailability of Dehydroepiandrosterone can be decreased when combined with Magnesium oxide.
dehydroepiandrosterone sulfateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium oxide.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide.
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium oxide.
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium oxide.
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium oxide.
DexmethylphenidateMagnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineMagnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium oxide.
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium oxide.
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium oxide.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium oxide.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide.
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium oxide.
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium oxide.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide.
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium oxide.
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium oxide.
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium oxide.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium oxide.
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium oxide.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium oxide.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide.
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium oxide.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide.
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium oxide.
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium oxide.
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium oxide.
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium oxide.
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium oxide.
FluphenazineMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium oxide.
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium oxide.
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium oxide.
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium oxide.
Fluticasone PropionateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium oxide.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide.
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.
GabapentinMagnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium oxide.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide.
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium oxide.
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.
Hydroxyamphetamine hydrobromideMagnesium oxide may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a lower serum level and potentially a reduction in efficacy.
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide.
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.
IsoniazidMagnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide.
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium oxide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide.
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide.
Lipoic AcidMagnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
LisdexamfetamineMagnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium oxide.
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium oxide.
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium oxide.
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium oxide.
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium oxide.
MephentermineMagnesium oxide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.
MesoridazineMagnesium oxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethamphetamineMagnesium oxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineMagnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blueMagnesium oxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethylphenidateMagnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium oxide.
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium oxide.
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol.
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium oxide.
MoricizineMagnesium oxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium oxide.
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium oxide.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium oxide.
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium oxide.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium oxide.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium oxide.
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium oxide.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide.
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide.
PerphenazineMagnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhentermineMagnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium oxide.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium oxide.
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium oxide.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium oxide.
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium oxide.
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide.
ProchlorperazineMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PromazineMagnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PromethazineMagnesium oxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
QuinidineMagnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Magnesium oxide.
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide.
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium oxide.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide.
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Magnesium oxide.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide.
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium oxide.
Technetium Tc-99m MedronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Magnesium oxide.
ThiethylperazineMagnesium oxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ThioridazineMagnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium oxide.
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium oxide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Magnesium oxide.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium oxide.
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium oxide.
TriethylenetetramineThe serum concentration of Magnesium oxide can be decreased when it is combined with Triethylenetetramine.
TriethylenetetramineMagnesium oxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TrifluoperazineMagnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TriflupromazineMagnesium oxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium oxide.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium oxide.
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium oxide.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on July 06, 2007 14:30 / Updated on September 24, 2016 02:17